DDB2: a novel regulator of NF-kappaB and breast tumor invasion.
Fiche publication
Date publication
août 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Dr JUNG Alain, Mme LEDRAPPIER Sonia, Dr PINEL Sophie
Tous les auteurs :
Ennen M, Klotz R, Touche N, Pinel S, Barbieux C, Besancenot V, Brunner E, Thiebaut D, Jung AC, Ledrappier S, Domenjoud L, Abecassis J, Plenat F, Grandemange S, Becuwe P
Lien Pubmed
Résumé
The DNA repair protein damaged DNA-binding 2 (DDB2) has been implicated in promoting cell-cycle progression by regulating gene expression. DDB2 is selectively overexpressed in breast tumor cells that are noninvasive, but not in those that are invasive. We found that its overexpression in invasive human breast tumor cells limited their motility and invasiveness in vitro and blocked their ability to colonize lungs in vivo, defining a new function for DDB2 in malignant progression. DDB2 overexpression attenuated the activity of NF-kappaB and the expression of its target matrix metalloprotease 9 (MMP9). Mechanistic investigations indicated that DDB2 decreased NF-kappaB activity by upregulating expression of IkappaBalpha by binding the proximal promoter of this gene. This effect was causally linked to invasive capacity. Indeed, knockdown of DDB2-induced IkappaBalpha gene expression restored NF-kappaB activity and MMP9 expression, along with the invasive properties of breast tumor cells overexpressing DDB2. Taken together, our findings enlighten understanding of how breast cancer cells progress to an invasive phenotype and underscore potential clinical interest in DDB2 as a prognostic marker or therapeutic target in this setting.
Référence
Cancer Res. 2013 Aug 15;73(16):5040-52